A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples